AVITA Medical reports Q2 2026 financial results
Key points
- Q2 net revenue grew 18% year-over-year to a record $21.7 million
- Gross profit margin increased to 81.9%
- Raised full-year 2026 net revenue guidance to $86M-$89M
- Expects to reach cash flow breakeven in Q4 2026
Full summary
AVITA Medical reported strong financial results for the second quarter of 2026. The company saw a significant increase in net revenue, growing 18% year-over-year to a record $21.7 million. This growth was driven by continued execution across the company's key commercial portfolio, led by RECELL, and supported by Cohealyx and PermeaDerm. Gross profit margin also improved to 81.9%, reflecting the growth of RECELL and the expansion of the company's product portfolio. AVITA Medical raised its full-year 2026 net revenue guidance to a range of $86 million to $89 million, reflecting confidence in continued commercial execution. Additionally, the company expects to achieve cash flow breakeven in the fourth quarter of 2026.
Guidance
Raised full-year 2026 net revenue guidance to $86M-$89M
Outlook
Expects to reach cash flow breakeven in Q4 2026
Summary generated by a large language model. Please interpret with care.